Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. (Q52599881)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 April 2010

Language	Label	Description	Also known as
English	Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.	scientific article published on 17 April 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

circadian rhythm

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Raphael Saffroy

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Catherine Guettier

8

object named as

Catherine Guettier

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

Francis Lévi

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Abdoulaye Karaboué

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Lee Gorden

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Pasquale Fabio Innominato

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Sylvie Giacchetti

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Dominique Hauteville

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

René Adam

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Mohamed Bouchahda

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

publication date

17 April 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

67

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

339-348

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

New treatment options for colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Central administration of transforming growth factor-alpha and neuregulin-1 suppress active behaviors and cause weight loss in hamsters

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Circadian rhythms: mechanisms and therapeutic implications

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Circadian orchestration of the hepatic proteome

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Implications of circadian clocks for the rhythmic delivery of cancer therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Circadian timing in cancer treatments.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1327-8

21 January 2018

Identifiers

10.1007/S00280-010-1327-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401611%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52599881&oldid=2211717028"